ERBB2 and neoplasm: The study of phenotypic changes occurring in these tumor cells during and after HER2-blocking therapy showed a switch to a low-proliferative luminal A phenotype, more evident in HR+ than in HR- tumors, associated with an increased sensitivity to CDK4/6 inhibitors [506].